⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Bio Farma and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Bio Farma
↗Bandung, Indonesia
PT Bio Farma (Persero) is an Indonesian state-owned enterprise and the nation's primary vaccine and antisera manufacturer. With a history spanning over 130 years, it plays a critical role in Indonesia's national immunization program and serves as a global supplier of vaccines, often collaborating with international organizations like WHO, UNICEF, and the Gates Foundation.
Since 2020, Bio Farma has operated as the holding company for Indonesia's state-owned pharmaceutical sector, overseeing subsidiaries including Kimia Farma and Indofarma. The company focuses on vaccine sovereignty, research and development in life sciences, and the integration of digital technologies to enhance pharmaceutical supply chain security and product traceability.
CLASSIFICATION
SIZE & FINANCIALS
Employees:2001-5000
Founded:1890
Ownership:government
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Vaccines, Sera, Diagnostics
Active Trials:48
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Kimia Farma, Indofarma, INUKI
Key Partnerships:Gates Foundation (Vaccine capacity), Serum Institute of India (TB diagnostics), Novo Nordisk (Insulin production), DCVMN (Global vaccine resilience)
COMPETITION
Position:Leader
Competitors:Jazz Pharmaceuticals, Sana Biotechnology, C4 Therapeutics
LEADERSHIP
Key Executives:
Shadiq Akasya - President Director
LINKS
Website:biofarma.co.id
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Bio Farma. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.